Home
Categories
EXPLORE
True Crime
Comedy
Society & Culture
Business
News
Sports
TV & Film
About Us
Contact Us
Copyright
© 2024 PodJoint
Podjoint Logo
US
00:00 / 00:00
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts125/v4/56/f2/b8/56f2b88c-f71b-11ca-2fa0-ecddc1044fe8/mza_2145894122309428224.jpg/600x600bb.jpg
MediCom Oncology Clinical Pearls Podcasts
MediCom Oncology
53 episodes
1 month ago
Dr. Perl provides a brief summary of what is on the horizon for FLT3 inhibitors in AML.
Show more...
Science
RSS
All content for MediCom Oncology Clinical Pearls Podcasts is the property of MediCom Oncology and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Dr. Perl provides a brief summary of what is on the horizon for FLT3 inhibitors in AML.
Show more...
Science
https://i1.sndcdn.com/artworks-000280786637-lb7d9e-t3000x3000.jpg
What are the unique aspects of pancreas cancer that lead to the development of novel therapeutics?
MediCom Oncology Clinical Pearls Podcasts
2 minutes 40 seconds
7 years ago
What are the unique aspects of pancreas cancer that lead to the development of novel therapeutics?
Dr. O'Reilly discusses the unique pathophysiology of pancreas cancer that must be considered in the development of novel therapeutics.
MediCom Oncology Clinical Pearls Podcasts
Dr. Perl provides a brief summary of what is on the horizon for FLT3 inhibitors in AML.